generic

Featured in Fortune article on Drug Patent Challenges

March 11, 2011

Fortune magazine recently published an article on the growing trend of generic companies challenging pharmaceutical drug patents. I enjoyed working with the writer to help layout the industry landscape, and share my knowledge of drug patents and trends from DrugPatentWatch.com. It’s a good read, and it does an excellent job of laying out the legal, [...]

Read the full article →

Patent Expirations Will Stabilize the Pharmaceutical Industry

November 15, 2010

“Patent Expirations Will Stabilize the Pharmaceutical Industry.” I must believe it, because I’m quoted in the St. Louis Observer as having said it! The reporter did a good job of capturing what I meant, quoting me as saying “the industry will be more diverse, with a more stable, though smaller, revenue base spread among many [...]

Read the full article →

When will the U.S. develop concise generic biologic rules?

September 22, 2008

A lot of people have been asking my opinion on when a concise generic biologic regulatory pathway will emerge in the United States, and I give them all the same answer: Later. In my opinion complex regulatory schemes are not areas in which the United States can effectively lead. Why not? Because the size of [...]

Read the full article →